Jim Cramer on Recursion Pharmaceuticals: “It’s a Let Down, Big Let Down”

Company Overview - Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotech company focused on accelerating drug discovery through automation, data science, and AI [1] - The company develops treatments for genetic, infectious, and cancer-related diseases [1] Market Sentiment - The stock has been described as "horrendous" by Jim Cramer, indicating a significant decline in performance [1] - Cramer expressed disappointment regarding the stock's performance, particularly in light of Cathie Wood's investment, suggesting it has not met expectations [1] Investment Perspective - There is acknowledgment of RXRX's potential as an investment, but it is noted that other AI stocks may offer greater upside potential with less downside risk [2] - The company is categorized as speculative, indicating a high-risk investment profile [1]